QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Forecast, Price & News

$1.80
+0.04 (+2.27%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.76
$1.93
50-Day Range
$1.73
$3.12
52-Week Range
$1.65
$16.00
Volume
29,032 shs
Average Volume
57,997 shs
Market Capitalization
$3.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Agile Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
372.2% Upside
$8.50 Price Target
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
1.00mentions of Agile Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.05) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars


AGRX stock logo

About Agile Therapeutics (NASDAQ:AGRX) Stock

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Price History

AGRX Stock News Headlines

Maxim Group Upgrades Agile Therapeutics (NASDAQ:AGRX) to Buy
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Agile Therapeutics (NASDAQ: AGRX)
Why Agile Therapeutics Stock Is Trading Higher Today
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Company Calendar

Last Earnings
8/09/2023
Today
9/25/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+369.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-25,410,000.00
Net Margins
-201.02%
Pretax Margin
-116.82%

Debt

Sales & Book Value

Annual Sales
$10.88 million
Book Value
($6.83) per share

Miscellaneous

Free Float
1,916,000
Market Cap
$3.50 million
Optionable
Optionable
Beta
1.13
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Alfred F. AltomariMr. Alfred F. Altomari (Age 64)
    Chairman, Pres & CEO
    Comp: $644.4k
  • Mr. Geoffrey P. Gilmore (Age 57)
    Sr. VP & Chief Admin. Officer
    Comp: $478.92k
  • Dr. Paul Korner M.B.A. (Age 57)
    M.D., Sr. VP & Chief Medical Officer
    Comp: $480.4k
  • Mr. Scott M. Coiante (Age 56)
    CFO, Sr. VP & Treasurer
  • Matthew Riley
    Head of Investor Relations & Corp. Communications
  • Mr. Robert G. Conway M.E. (Age 65)
    Sr. VP and Chief Corp. Planning & Supply Chain Officer
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D. (Age 55)
    M.P.H., Consultant
  • Ms. Amy Welsh (Age 52)
    Sr. VP & Chief Commercial Officer
  • Joseph D'Urso
    Controller













AGRX Stock - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings
or view top-rated stocks.

What is Agile Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 12-month target prices for Agile Therapeutics' shares. Their AGRX share price forecasts range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.50 in the next year. This suggests a possible upside of 369.0% from the stock's current price.
View analysts price targets for AGRX
or view top-rated stocks among Wall Street analysts.

How have AGRX shares performed in 2023?

Agile Therapeutics' stock was trading at $0.2270 at the start of the year. Since then, AGRX stock has increased by 698.3% and is now trading at $1.8122.
View the best growth stocks for 2023 here
.

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 10,700 shares, a decrease of 48.3% from the August 15th total of 20,700 shares. Based on an average trading volume of 119,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the shares of the stock are short sold.
View Agile Therapeutics' Short Interest
.

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AGRX earnings forecast
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.48) by $0.38. The specialty pharmaceutical company earned $5.50 million during the quarter, compared to analysts' expectations of $4.68 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 2,658.43% and a negative net margin of 201.02%.

When did Agile Therapeutics' stock split?

Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (1.10%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $1.81.

How much money does Agile Therapeutics make?

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.50 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($39.56) on an earnings per share basis.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.

This page (NASDAQ:AGRX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -